key: cord-0962437-vt7cw4rb
authors: Smith, Maria; Lara, Olivia D.; O'Cearbhaill, Roisin; Knisely, Anne; McEachron, Jennifer; Gabor, Lisa; Carr, Caitlin; Blank, Stephanie; Prasad-Hayes, Monica; Frey, Melissa; Jee, Justin; Fehniger, Julia; Wang, Yuyan; Lee, Yi-chun; Isani, Sara; Wright, Jason D.; Pothuri, Bhavana
title: Inflammatory markers in gynecologic oncology patients hospitalized with COVID-19 infection
date: 2020-09-25
journal: Gynecol Oncol
DOI: 10.1016/j.ygyno.2020.09.036
sha: 95adc2c4959aae2ad8012c6fb21273738bc0d1d9
doc_id: 962437
cord_uid: vt7cw4rb

Objective: Elevated inflammatory markers are predictive of COVID-19 infection severity and mortality. It is unclear if these markers are associated with severe infection in patients with cancer due to underlying tumor related inflammation. We sought to further understand the inflammatory response related to COVID-19 infection in patients with gynecologic cancer. Methods: Patients with a history of gynecologic cancer hospitalized for COVID-19 infection with available laboratory data were identified. Admission laboratory values and clinical outcomes were abstracted from electronic medical records. Severe infection was defined as infection requiring ICU admission, mechanical ventilation, or resulting in death. Results: 86 patients with gynecologic cancer were hospitalized with COVID-19 infection with a median age of 68.5 years (interquartile range (IQR), 59.0–74.8). Of the 86 patients, 29 (33.7%) patients required ICU admission and 25 (29.1%) patients died of COVID-19 complications. Fifty (58.1%) patients had active cancer and 36 (41.9%) were in remission. Patients with severe infection had significantly higher ferritin (median 1163.0 vs 624.0 ng/mL, p < 0.01), procalcitonin (median 0.8 vs 0.2 ng/mL, p < 0.01), and C-reactive protein (median 142.0 vs 62.3 mg/L, p = 0.02) levels compared to those with moderate infection. White blood cell count, lactate, and creatinine were also associated with severe infection. D-dimer levels were not significantly associated with severe infection (p = 0.20). Conclusions: The inflammatory markers ferritin, procalcitonin, and CRP were associated with COVID-19 severity in gynecologic cancer patients and may be used as prognostic markers at the time of admission.

As global confirmed cases of SARS-CoV-2 (COVID-19) disease surpass 16 million and many experts predict a second wave of infections [1] , it is imperative to understand the interactions between COVID-19 infection and oncologic disease. Initial reports have found high mortality rates in patients with cancer [2, 3] and have demonstrated significant variation in mortality rates among different cancer types [4] . Prospective and retrospective studies of COVID-19 mortality in the US, Canada, and UK have demonstrated COVID-19 mortality rates between 17-28% among patients with active malignancy [4] [5] [6] . In a prior study, the present authors noted a mortality rate of 14% among gynecologic oncology patients in New York City (NYC) [7] .

In patients with COVID-19 infection, inflammatory markers including C-reactive protein (CRP), procalcitonin, erythrocyte sedimentation rate (ESR), interleukin-6 (IL-6), and ferritin have been shown to be significantly higher in severe disease [8] . Elevated IL-6 has also been associated with increased mortality from COVID-19 [8, 9] . The excessive immune response to COVID-19 triggers a cytokine storm, leading to rapid clinical deterioration, acute respiratory distress syndrome (ARDS), and multiorgan failure [10] . Ongoing clinical trials investigating the role of both anti-inflammatory agents such as corticosteroids (NCT04344288) and immune modulating agents such as nivolumab (NCT04343144) in COVID-19 treatment.

Despite the growing understanding of the role of the immune system and inflammation in COVID-19 among the general population, it is unclear which principles can be applied to oncology patients with COVID-19 as cancer is known to alter inflammatory and immunologic states in the body. Systemic inflammation has been demonstrated in many cancer types and has J o u r n a l P r e -p r o o f Journal Pre-proof been associated with worse survival outcomes [11, 12] . Chronic inflammation can both be the cause of malignancy or the result [13] . Inflammatory conditions such as chronic pancreatitis, inflammatory bowel disease, and hepatitis are all associated with increased risk of malignancy in the inflamed tissue [14] [15] [16] . Alternatively, tumor cells and the tumor microenvironment can express cytokines and other signaling molecules of the innate immune system throughout growth, invasion, and metastasis [13] . Chronic inflammation may lead to an immunosuppressed environment via a compensatory activation of immune suppressor cells [17] . Patients with diminished tumor-directed immune response have been found to have worse prognosis compared to those with a robust immune response [12, 18] . Anti-cancer treatments can also contribute to systemic immunodeficiencies in oncology patients [19] .

Although inflammatory markers in COVID-19 infection are predictive of disease severity and mortality in the general population, given the changes in systemic inflammatory and immune responses in cancer patients, it is unclear if these markers are associated with severe disease in patients with malignancy. Our aim was to describe inflammatory responses related to COVID-19 in patients with a history of or active gynecologic cancer to identify if inflammatory markers can be used as prognostic tools in this patient population.

Patients were considered to have COVID-19 infection if they had laboratory-confirmed diagnosis, imaging-based diagnosis (including chest radiography or chest computed tomography), or if there was a high clinical suspicion for COVID-19 and they were treated based on COVID-19 hospital protocols. This study was approved by Institutional Review Boards at all participating sites.

Patient data was accessed from the electronic medical record at each of the participating centers and was stored in Research Electronic Data Capture software (REDCap, Vanderbilt University) [20] . Abstracted data included patient demographics, COVID-19 severity (severe vs moderate), COVID-19 outcome (death vs recovered), cancer type, cancer stage, and cancer treatment.

Severe disease was defined as COVID-19 infection requiring ICU admission, mechanical ventilation or death due to COVID-19 infection. Moderate disease was defined as COVID-19 infection requiring hospitalization but not requiring ICU admission, mechanical ventilation or resulting in death. For each patient, the following laboratory test values at the time of admission were collected: white blood cell count, absolute neutrophil count, lymphocyte count, hemoglobin, platelets, aspartate aminotransferase, alanine aminotransferase, lactate, lactate dehydrogenase, serum creatinine, troponin, total bilirubin, ferritin, D-dimer, procalcitonin, and C-reactive protein.

Patient categorical data was summarized using frequencies and percentages and continuous variables were summarized as medians (interquartile ranges). The Shapiro-Wilk test was utilized J o u r n a l P r e -p r o o f Journal Pre-proof to assess for normality. The t-test and Wilcoxon rank-sum test was used to compare continuous variables, and categorical variables were compared using Chi-square test or Fisher's exact test. A p-value < 0.05 was considered statistically significant. All statistical analyses were performed using R version 4.0.2.

A total of 181 patients were identified with gynecologic cancer and COVID-19 infection. There were 99 (54.7%) patients hospitalized for moderate or severe infections, and of admitted patients 86 (86.9%) had available laboratory data and were included in the analysis. Patient demographic and cancer characteristics are described in Table 1 Laboratory values were also compared between patients with active cancer and those in remission (Table 3) . Hemoglobin was significantly lower in patients with active cancer (median 

This multi-center study of gynecologic cancer patients hospitalized for COVID-19 infection found that the inflammatory markers ferritin, procalcitonin, and C-reactive protein were significantly higher at the time of admission in patients who went on to develop severe infection requiring ICU admission, mechanical ventilation, or resulting in death. Higher white blood cell count, creatinine, and lactate were also associated with severe COVID-19 infection. These findings in patients with a known history of gynecologic cancer are consistent with prior studies of inflammatory, hematologic, and coagulation markers in COVID-19 infection. Two independent meta-analyses of inflammatory markers in COVID-19 infection among the general population have reported significantly higher inflammatory markers in patients with severe COVID-19 and COVID-19 mortality, including CRP, ESR, ferritin, procalcitonin, and IL-6 [9, 21] . One meta-analysis also found significant associations between hematologic markers and COVID-19 severity and death, including WBC and D-dimer. Furthermore, when admission inflammatory markers between patients with active gynecologic cancer and in remission were compared, except for a decrease of hemoglobin in patients with active cancer, no differences in laboratory values between patients with active cancer and those in remission were noted. A significant decrease in hemoglobin in patients with active cancers can be attributed to a variety of reasons including vaginal bleeding associated with gynecologic malignancy, anemia of chronic disease, or chemotherapy induced anemia [22] [23] [24] .

As acute phase reactants, inflammatory markers such as ferritin and CRP are non-specific markers of inflammation and can be elevated in both patients with cancer and active infection [25] . Ferritin binds iron intracellularly and is an indirect marker of total body iron stores [26] and during infection its role is to sequester iron and prevent its uptake by microbes [27] . CRP is J o u r n a l P r e -p r o o f Journal Pre-proof secreted by hepatocytes in response to IL-6 secreted by macrophages and works to opsonize microbes and necrotic or apoptotic cells so they can be phagocytosed [28] . Procalcitonin is typically thought to be elevated in bacterial, fungal, and protozoal infections rather than viral infections [29] . In COVID-19 infection, however, one meta-analysis demonstrated increased procalcitonin levels were associated with a five-fold higher risk of developing severe COVID-19 infection in the general population [30] . The use of procalcitonin levels as a marker for infection has been controversial in cancer patients. Studies have demonstrated that patients with solid tumors have higher baseline procalcitonin than patients in remission or without a history of cancer, and patients with more advanced cancer have higher procalcitonin than those with earlystage disease [31, 32] . In this cohort, despite finding a non-significant elevation of these inflammatory markers in patients with active cancer compared to remission, ferritin, procalcitonin, and CRP at hospital admission still had prognostic value in predicting the severity of COVID-19 infection.

No significant difference in D-dimer levels between moderate and severe COVID-19 infections were identified in these data. One study of D-dimer levels in hospitalized patients with COVID-19 determined D-dimer greater than 2000 ug/L was predictive of in-hospital mortality with a sensitivity of 92.3% and a specificity of 83.3% [33] . In our study population there was 

Beware of the second wave of COVID-19

Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the

Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study

COVID-19 outcomes of patients with gynecologic cancer

Association of inflammatory markers with the severity of COVID-19: A meta-analysis

Elevated interleukin-6 and severe COVID-19: A meta-analysis

The pathogenesis and treatment of the

Lactate dehydrogenase A in cancer: a promising target for diagnosis and therapy

Patient inflammatory status and CD4+/CD8+

intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer

Chronic inflammation, immunosuppression and cancer: new insights and outlook

Chronic Pancreatitis and Pancreatic Cancer Risk: A Systematic Review and Meta-analysis

Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies

Epidemiology of viral hepatitis and hepatocellular carcinoma

Immunosuppression associated with chronic inflammation in the tumor microenvironment

Level of tumor-infiltrating lymphocytes and density of infiltrating immune cells in different malignancies

Trends in recommendations for myelosuppressive chemotherapy for the treatment of solid tumors

Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support

Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis

Abnormal uterine bleeding associated with iron-deficiency anemia. Etiology and role of hysteroscopy

Understanding anemia of chronic disease

Chemotherapy-induced anemia in adults: incidence and treatment

Acute-phase proteins and other systemic responses to inflammation

Ferritin, cellular iron storage and regulation

Role of the hepcidin-ferroportin axis in pathogen-mediated intracellular iron sequestration in human phagocytic cells

C-reactive protein: a critical update

Use of procalcitonin in clinical oncology: a literature review

Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis

Role of Procalcitonin and Interleukin-6 in Predicting Cancer, and Its Progression Independent of Infection

Can procalcitonin distinguish infectious fever from tumor-related fever in non-neutropenic cancer patients?

D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19

Coagulation and cancer: biological and clinical aspects

The authors thank NYU Gynecologic Oncology practitioners at Tisch, Brooklyn and Winthrop campus Kari Hacker, Ghadir Salame, Franco Muggia, Edward Jimenez and Kathleen Lutz for identifying patients and details for this analysis. The authors also thank MSK Gynecologic Medical Oncology Service for identifying patients and details for this analysis.